Capricor Therapeutics, Inc. (CAPR) Stock Analysis & Investment Frameworks
Capricor Therapeutics, Inc. (CAPR) stock analysis on Invetso. Review Capricor Therapeutics, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Capricor Therapeutics, Inc. Company Overview
- Exchange: NASDAQ
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Capricor Therapeutics, Inc. Key Financial Metrics
- Market Cap: $515.73M
- Revenue: $N/A
- ROE: -56.60%
- ROIC: -40.08%
- Dividend Yield: N/A
About Capricor Therapeutics, Inc.
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.